57 completed, 2 terminated, 2 unknown, 1 active not recruiting. 40 Phase 1, 9 Not applicable, 9 Phase 3, 3 Early Phase 1, 2 Phase 2.
Follow Reference product: new trials by email Literature Review of Reference product trials Research Report on Reference product
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing Ivermectin Cream 1%, Soolantra™ Cream 1%, PrROSIVER® Cream1% to Placebo Control in the Treatment of Moderate to Severe Facial Rosacea. Ivermectin Cream 1%, Soolantra™ Cream 1%, PrRosiver® Cream 1% - Rosacea | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 865 | 2025-12-09 | 2026-08-31 |
| A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis. Tapinarof Cream, 1%, Vtama® (Tapinarof) Cream, 1%, Placebo Control - Plaque Psoriasis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 575 | 2025-10-13 | 2026-04-22 |
| A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris Tretinoin Gel Microsphere, 0.04%, RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04%, Placebo Control - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1043 | 2025-08-04 | 2026-03-13 |
| Effects of In-between Meal Products on Cognitive Function in the Elderly Minimeal product, Reference product - Cognitive Function | Not applicable | Active not recruiting | Örebro University, Sweden | 114 | 2024-08-26 | 2026-02-18 |
| A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 1000 | 2024-06-20 | 2024-12-13 |
| A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris. Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel, Placebo Control - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 382 | 2024-05-13 | 2024-11-05 |
| A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema Ranibizumab 10mg/ml Injection, Lucentis - Diabetic Macular Edema, Diabetic Retinopathy | Phase 3 | Completed | Incepta Pharmaceuticals Ltd | 70 | 2024-03-30 | 2026-09-25 |
| A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche) Trastuzumab (proposed Trastuzumab biosimilar), Herclon - Breast Cancer, Breast Neoplasms | Phase 1 | Completed | Incepta Pharmaceuticals Ltd | 80 | 2024-01-23 | 2025-07-22 |
| A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor. Ketoconazole Shampoo, 2%, Ketoconazole Shampoo, 2% (Reference Standard), Placebo - Tinea Versicolor | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 430 | 2023-12-04 | 2024-03-12 |
| Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route Test Product, Reference product, Reference Medicinal Product - Rheumatoid Arthritis | Phase 1 | Unknown | Dr. Reddy's Laboratories Limited | 330 | 2023-10-03 | 2023-11-13 |
| A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis. Ruxolitinib Topical Cream 1.5%, OPZELURA (Ruxolitinib) Cream, Placebo - Atopic Dermatitis | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 476 | 2023-08-11 | 2024-11-05 |
| A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris Trifarotene Cream 0.005%, Placebo, AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories) - Acne Vulgaris | Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 762 | 2023-02-22 | 2023-10-02 |
| Ibuprofen Liquid Capsules 2 x 200 mg Efficacy and PK/PD Study in Surgical Removal of Impacted Third Molars Ibuprofen 200Mg Oral Cap, Ibuprofen 200Mg Oral Tablet, Placebo Liquid Capsule - Tooth, Impacted, Tooth Diseases | Phase 3 | Completed | Reckitt Benckiser Healthcare (UK) Limited | 294 | 2022-08-09 | 2023-06-22 |
| Second Meal Effects of a Wholegrain Cereal Product on Blood Glucose Response Reference Product, Wholegrain product Dose A, Wholegrain product Dose B - Blood Glucose Response | Not applicable | Completed | Aventure AB | 17 | 2022-03-17 | 2022-07-05 |
| Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study) Oxervate, Vehicle - Dry Eye | Phase 3 | Completed | Dompé Farmaceutici S.p.A | 104 | 2022-01-19 | 2024-06-07 |
| A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis. Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%, Placebo - Plaque Psoriasis | Early Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 402 | 2021-04-16 | 2022-03-16 |
| Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Feeding Conditions Duloxetine 60mg Test Drug Enteric Coated Granules, Duloxetine 60mg Reference Product Enteric Coated Granules - Bioequivalence | Phase 1 | Completed | Laboratorios Andromaco S.A. | 36 | 2021-02-27 | 2021-04-15 |
| A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris Tretinoin Gel Microsphere, 0.1%, RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%, Placebo Control - Acne Vulgaris | Early Phase 1 | Completed | Sun Pharmaceutical Industries, Inc. | 973 | 2020-08-31 | 2021-05-12 |
| A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers Test Product, Reference Product - Bioequivalence | Phase 1 | Completed | Respirent Pharmaceuticals Co Ltd. | 34 | 2020-07-01 | 2021-03-09 |
| Effect of Nordic Berries on Cognitive Function, Cardiometabolic Risk Markers and Gut Microbiota in Adults With Mild Cognitive Impairment Active berry product, Reference product - Cognitive Impairment, Mild, Memory Impairment | Not applicable | Completed | Region Skane | 96 | 2020-06-03 | 2024-03-01 |
Showing 20 of 62. Sign in to see all of them.
Fasting (9) · Acne Vulgaris (7) · Asthma (5) · Lecithin Cholesterol Acyltransferase Deficiency (4) · Surgical Wound Infection (2) · Amyotrophic Lateral Sclerosis (1) · Arthritis, Rheumatoid (1) · Breast Diseases (1) · Breast Neoplasms (1) · Cognitive Dysfunction (1) · Dermatitis, Atopic (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Diabetic Retinopathy (1) · Dry Eye Syndromes (1)
IPCA Laboratories Ltd. (13) · Sun Pharmaceutical Industries, Inc. (11) · Actavis Inc. (5) · GlaxoSmithKline (3) · Respirent Pharmaceuticals Co Ltd. (3) · Amneal Ireland Limited (2) · Incepta Pharmaceuticals Ltd (2) · Lupin Ltd. (2) · Zurex Pharma, Inc. (2) · Arbor Pharmaceuticals, Inc. (1) · Aurobindo Pharma Ltd (1) · Aventure AB (1) · Biogen (1) · Derming SRL (1) · Dompé Farmaceutici S.p.A (1)
United States (25) · India (16) · Greece (3) · Sweden (3) · Bangladesh (2) · Belgium (2) · Canada (2) · Chile (2) · Argentina (1) · Austria (1) · Brazil (1) · Bulgaria (1) · China (1) · Colombia (1) · Germany (1)
Natalie Yantovskiy (7) · Dr. Hardik Dave, M.B.B.S (4) · Dr. Hardik Dave, M.B.B.S. (4) · Daniel V. Freeland, DO (3) · Ioannis Stefanidis, Professor (3) · Zaidoon A. Al-Zubaidy (3) · Dr. Manish Singhal, M.B.B.S (2) · Dr. Tarang Girishbhai Shah, M. D. (Pharmacology) (2) · Irshad Haque (2) · James P. Doherty, DO (2) · Satyanarayana V, M.Pharma., Ph.D (2) · Wilfried De Backer, MD, PhD (2) · Andy Silverman (1)
PMID 27227384, PMID 27668024, PMID 32026625, PMID 42752400
2014 (1)